Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MDCX vs GRML: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MDCX Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 7–1 Matrix Metrics)

MDCX Overall Winner 6-Pillar Tally: MDCX 3 – 0 GRML (3 Tie) Matrix Metrics: MDCX 7 – 1 GRML

As of Nov 16, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MDCX carries a Unified Composite Score of 61.9/100 (BUY) at $1.68 (N/M Forward P/E, 0.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MDCX vs GRML
MDCX NASDAQ Head-to-Head Winner
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.68
-13.85% 1D
Market Cap $3.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -1.42β · 108% Vol
Unified Composite Score
61.9 / 100 BUY
Tech 83.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.2 · SMA20: $2.11 · SMA50: $1.31
GRML US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -5.32β · 95% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.5 · SMA20: $4.67 · SMA50: $6.11

6-Pillar Scorecard Institutional Category Breakdown (MDCX 3 – 0 GRML)

Columns: Metric · MDCX · GRML
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MDCX
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $3.6M N/A
3. Profitability & Quality MDCX
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -7446.1% N/A
4. Balance Sheet & Cash Flow MDCX
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.8M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MDCX (7) vs GRML (1)
Institutional Metric MDCX GRML Criterion Row Edge
Market Capitalization
Scale
$3.6M N/A Larger Scale MDCX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth MDCX
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin MDCX
Net Profit Margin
Profitability
0.0% N/A Higher Margin MDCX
Return on Equity (ROE)
Capital Efficiency
-7446.1% N/A Higher ROE MDCX
52-Week Range Position
Momentum
35% ($0–$5) 19% ($0–$18) Stronger Trend MDCX
Beta / 30D Volatility
Risk Regime
-1.42β · 108% Vol -5.32β · 95% Vol Lower Realized Risk GRML
Unified Institutional Score
Composite Signal
61.9 / 100 (BUY) 56.8 / 100 (HOLD) Higher Composite MDCX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($3.8M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRML +6.81 pp
MDCX: -48.31% · GRML: -41.5%
3M Horizon GRML +1228.96 pp
MDCX: +538.06% · GRML: +1767.02%
6M Horizon GRML +416.93 pp
MDCX: +477.12% · GRML: +894.05%
1Y Horizon GRML +414.0 pp
MDCX: +236.0% · GRML: +650.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDCX vs GRML. Trailing 12-month operating profitability (MDCX 0.0% vs GRML N/A) and valuation multiples (MDCX N/M vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MDCX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-7446.1% · N/M
GRML ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MDCX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MDCX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRML UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GRML Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MDCX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $3.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GRML Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MDCX vs GRML Key Questions & Quantitative Answers

As of Nov 16, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MDCX carries a Unified Composite Score of 61.9/100 (BUY) at $1.68 (N/M Forward P/E, 0.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin). Technically, MDCX sits in a Neutral phase (RSI 46.2, UNCLASSIFIED options structure) and GRML sits in a Neutral phase (RSI 37.5, UNCLASSIFIED options structure).

MDCX leads the Growth & Scale pillar: MDCX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GRML at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MDCX generates N/A in USD-normalized revenue versus N/A for GRML. In operating R&D and SG&A reinvestment, MDCX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRML.

MDCX and GRML trade at balanced relative valuation multiples. MDCX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MDCX (-7446.1% ROE) versus GRML (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, MDCX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.42β · 108% Vol realized risk). By comparison, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.